Catheter Precision, Inc. is a small-cap medical device company focused on neuromodulation therapies for heart failure, engaged in asset acquisitions and development activities.

# Company Summary: Catheter Precision, Inc.

**Business Focus:**  
Catheter Precision, Inc. is a medical device company specializing in the development and commercialization of neuromodulation therapies, specifically for the treatment of heart failure. The company is engaged in acquiring and developing assets related to late-stage treatments in this area, with a focus on neuromodulation technology.

**Operational Highlights:**  
- **Asset Acquisition:**  
  In April 2025, Catheter Precision agreed to acquire certain assets of Cardionomic, Inc., a company working on treatments for acute decompensated heart failure. The acquisition includes a $1.5 million promissory note and 1,000,000 shares of restricted common stock.

- **Subsidiary Formation:**  
  Formed a Nevada subsidiary, Cardionomix, Inc., to pursue asset acquisition opportunities and development of treatments related to heart failure.

- **Product Development & Trials:**  
  The company is working on neuromodulation devices aimed at treating heart failure, with ongoing pilot studies and potential FDA review, which are costly and lengthy. No specific data on trial outcomes or product approval status has been provided.

- **Regulatory & Compliance:**  
  The company is subject to FDA regulatory requirements and has experienced some historic issues with internal controls, but details on specific certifications, product approvals, or market presence are not provided.

**Financial & Market Data:**  
- **Number of Shares Outstanding:**  
  As of March 17, 2025, there are 9,268,632 shares of common stock outstanding.

- **Market Capitalization:**  
  The approximate market value of the company's stock held by non-affiliates was about **$3.9 million** as of June 30, 2024.

- **Revenue and Income:**  
  No specific figures for revenue, net income, or operating income are included in the provided document.

**Employees & Customers:**  
- **Employees:**  
  The document does not specify the total number of employees.

- **Customers:**  
  No information about the company's customer base, number of customers, or revenue from sales is provided.

**Overall:**  
Catheter Precision, Inc. is a small-cap, development-stage medical device company focused on neuromodulation therapies for heart failure, involved in complex asset acquisitions, several warrant and equity financings, and strategic asset purchases. Specific operational metrics such as revenue, income, or customer numbers are not included in the provided text.

Catheter Precision, Inc. is a medical technology company specializing in innovative solutions for cardiac electrophysiology, notably the VIVO System.

# Company Overview: Catheter Precision, Inc.

## Business Summary
Catheter Precision, Inc. is a medical technology company focused on developing, commercializing, and marketing innovative medical technologies in the field of cardiac electrophysiology (EP). The company shifted its primary focus towards electrophysiology after merging with Catheter Precision, Inc. on January 9, 2023, and subsequently discontinued its legacy business related to the DABRA product line.

## Products
### 1. **VIVO System**
- **Description**: A non-invasive imaging system providing 3D cardiac mapping to localize the origins of idiopathic ventricular arrhythmias in patients with structurally normal hearts.
- **Usage**: Used in more than 1,000 procedures globally by over 30 physicians across 10 countries.
- **Revenue Generation**: The VIVO System has been the main source of revenue for the company since the merger, contributing to approximately $442,000 in product sales for the year ended December 31, 2023.

### 2. **LockeT**
- **Description**: A suture retention device aiding in wound healing by distributing suture tension over a larger area in conjunction with a figure-of-eight suture closure.
- **Status**: Registered with the FDA in February 2023, with CE Mark approval expected in the second half of 2024.

### 3. **Amigo® Remote Catheter System**
- **Description**: A robotic catheter control device aimed at facilitating catheter procedures.
- **Current Status**: Under consideration for future research and development of a generation 2 product.

## Market Position
- **Market Overview**: The electrophysiology market is rapidly expanding, projected to reach an estimated $15.1 billion by 2028, with a CAGR of 13%.
- **Catheter Ablation Market**: Focused on the catheter ablation segment, which was valued at $3.2 billion in 2020 and is expected to grow at a CAGR of 12.4% through 2026.

## Financials
- **Revenue**: For the fiscal year ended December 31, 2023, Catheter Precision reported $442,000 in revenue attributed to the VIVO system.
- **Expenses**: Key expenses included $30,000 in cost of revenues, $17.1 million in selling, general and administrative expenses, and a notable $60.9 million goodwill impairment charge.
- **Losses**: The company recorded a net loss of approximately $70.6 million for 2023, adding to an accumulated deficit of approximately $275.7 million.

## Employees
- **Total Employees**: As of March 12, 2024, the company had 14 full-time employees and retained 5 independent contractors.
- **Key Management**: David A. Jenkins (Executive Chairman and CEO) and Margrit Thomassen (Interim CFO) are part of the executive leadership team.

## Customer Base
- **Customer Reach**: The company has approximately 2,000 to 3,000 electrophysiology labs in the U.S. and an equivalent number internationally, performing about 600,000 ablation procedures annually.

## Conclusion
Catheter Precision is positioned to become a leading entity in the cardiac electrophysiology market with innovative products like the VIVO System and LockeT. Despite current financial challenges with significant losses and an ongoing need for capital, the company's commitment to addressing the underserved needs in cardiac arrhythmias presents a considerable opportunity for future growth in this rapidly expanding market.

Catheter Precision, Inc.

10-K / April 30, 2025

10-K / April 1, 2024

10-K / April 30, 2025

Company Summary: Catheter Precision, Inc.